Tumor-targeting nanoimmunoliposome complex for short interfering RNA delivery
Kathleen F Pirollo1, Gerald Zon, Antonina Rait
1Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20057, USA.
Abstract:
The potential of short interfering RNA (siRNA) to be developed for therapeutic use against cancer depends on the availability of an efficient tumor-specific delivery vehicle. We have previously shown that a nanoscale nonviral liposome-based complex that includes an anti-transferrin receptor single-chain antibody fragment as the targeting moiety can, when systemically administered, specifically and efficiently target primary and metastatic tumors and deliver molecules useful in gene medicine, including plasmid DNA and antisense oligonucleotides. Here we explore the ability of this complex to deliver a fluorescein-labeled siRNA to tumor cells in vivo and examine the intracellular localization in vitro by confocal microscopy. We show that the immunoliposome--siRNA complex maintains its nanoscale size and, using three separate tumor models, can efficiently and specifically deliver siRNA to both primary and metastatic disease after systemic delivery, thus increasing the possibility for translating the potent effects of siRNA observed in vitro into clinically useful therapeutics.
Insights
This study demonstrates that a targeted liposome delivery system can efficiently deliver short interfering RNA (siRNA) to tumors. This advance enhances the potential of siRNA therapeutics for cancer treatment.
Area of Science:
- Nanomedicine
- Cancer Therapeutics
- Molecular Biology
Background:
- Effective cancer treatment with short interfering RNA (siRNA) requires efficient tumor-specific delivery vehicles.
- Previous research established a nanoscale liposome complex with an anti-transferrin receptor antibody fragment for targeted delivery of gene medicine molecules.
Purpose of the Study:
- To evaluate the capacity of the established liposome complex to deliver siRNA to tumor cells in vivo.
- To examine the intracellular localization of siRNA within tumor cells in vitro using confocal microscopy.
Main Methods:
- Systemic administration of a fluorescein-labeled siRNA encapsulated within the immunoliposome complex.
- In vivo studies utilizing three distinct tumor models to assess delivery efficiency and specificity.
- In vitro confocal microscopy to determine intracellular siRNA localization.
Main Results:
- The immunoliposome--siRNA complex maintained its nanoscale integrity post-administration.
- Efficient and specific delivery of siRNA to both primary and metastatic tumors was achieved in all three models after systemic delivery.
- Intracellular localization studies confirmed uptake within tumor cells.
Conclusions:
- The targeted liposome complex demonstrates significant potential as a delivery vehicle for siRNA cancer therapeutics.
- Successful in vivo delivery of siRNA to tumors supports the translation of potent in vitro siRNA effects into clinical applications.
- This targeted delivery approach overcomes a key hurdle in developing siRNA-based cancer therapies.
Related Concept Videos
02:15Experimental RNAi
02:30siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
01:23RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
02:39lncRNA - Long Non-coding RNAs
02:30Small interfering RNAs (siRNA)
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...